Last reviewed · How we verify

JR-141 — Competitive Intelligence Brief

JR-141 (JR-141) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme replacement therapy. Area: Rare genetic/lysosomal storage disorders.

phase 3 Enzyme replacement therapy Arylsulfatase A Rare genetic/lysosomal storage disorders Small molecule Live · refreshed every 30 min

Target snapshot

JR-141 (JR-141) — JCR Pharmaceuticals Co., Ltd.. JR-141 is a recombinant human arylsulfatase A enzyme designed to cross the blood-brain barrier and replace deficient enzyme activity in lysosomal storage disorders.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
JR-141 TARGET JR-141 JCR Pharmaceuticals Co., Ltd. phase 3 Enzyme replacement therapy Arylsulfatase A
Pancrelipase Capsules Pancrelipase Capsules Ohio State University marketed Pancreatic enzyme replacement therapy
Elelyso Taliglucerase Alfa Pfizer Inc. marketed Enzyme replacement therapy Glucocerebroside (substrate); mannose receptors on cell surface
Naglazyme® Naglazyme® Masonic Cancer Center, University of Minnesota marketed Enzyme replacement therapy Arylsulfatase B (ARSB)
agalsidase beta (GZ419828) agalsidase beta (GZ419828) Sanofi marketed Enzyme replacement therapy Alpha-galactosidase A
creon 35.000 Ph.U (R) creon 35.000 Ph.U (R) Hospital Clinico Universitario de Santiago marketed Pancreatic enzyme replacement therapy
Fabrazyme (agalsidase beta) Fabrazyme (agalsidase beta) Genzyme, a Sanofi Company marketed Enzyme replacement therapy (ERT); recombinant enzyme α-galactosidase A (GLA gene product); substrate: globotriaosylceramide (GL-3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzyme replacement therapy class)

  1. BioMarin Pharmaceutical · 5 drugs in this class
  2. Sanofi · 3 drugs in this class
  3. JCR Pharmaceuticals Co., Ltd. · 2 drugs in this class
  4. Genzyme, a Sanofi Company · 2 drugs in this class
  5. Pfizer Inc. · 1 drug in this class
  6. Shire · 1 drug in this class
  7. Alexion Pharmaceuticals, Inc. · 1 drug in this class
  8. University of Missouri-Columbia · 1 drug in this class
  9. Eurofarma Laboratorios S.A. · 1 drug in this class
  10. ISU Abxis Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). JR-141 — Competitive Intelligence Brief. https://druglandscape.com/ci/jr-141. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: